News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Announcement
Horizon Scanning in Oncology - Reports
We are pleased to introduce our two new HSO reports.
DSD HSO No. 79
Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
Newsletter
Event archive
Event
1st Workhop of EUnetHTA Task Force on HTA & Medical Device Regulation
Tuesday, May 29th 2018, 9:00 AM to 5:30 PM
Gesellschaft der Ärzte
Frankgasse 8, 1090 Vienna
By invitation only
Event
Philosophical Dialogue on 'Individual vs. collective benefit: Can the greatest possible benefit be calculated? Can the individual understand collective benefits?'
This Information is available in German only.
Newsletter
Announcement
Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA report
Since several years, numerous new non-invasive prenatal tests (NIPTs) have been available to identify common chromosomal anomalies. Most NIPTs are available for trisomies 21, 18 and 13 and sex chromosome aneuploidies, but many laboratories have expanded their range of analysis to include other trisomies and common microdeletions. The main advantage of NIPT compared to the conventional screening approach is the ease of implementation and non-invasiveness of the assay, as well as the potential reduction in false-positive [FP] results. An introduction of non-invasive genetic testing has ethical, social and organizational implications that need to be considered.
Publication: LBI-HTA Project report No. 103: https://eprints.aihta.at/1153/
Contact: Claudia Wild
Announcement
Horizon Scanning in Oncology - Reports
We are pleased to introduce our new HSO report.
DSD HSO No. 77
Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)